UltraGreen.ai Limited, a global leader in fluorescence-guided surgery and digital health solutions, has announced regulatory approval for Verdye (indocyanine green for injection) in Singapore. This approval represents a strategic step in the company’s Southeast Asia growth strategy, expanding its addressable market and strengthening its presence in a key regional healthcare hub.
Singapore plays a critical role as a centre for clinical excellence and regional influence, supporting broader adoption of advanced surgical technologies across Southeast Asia.
This approval enables UltraGreen.ai to advance commercialisation efforts, deepen partnerships with leading healthcare institutions, and support clinical adoption of fluorescence-guided surgery. Fluorescence-guided surgery using Indocyanine Green (ICG) is now widely adopted across multiple surgical specialties, including oncology, colorectal, reconstructive, and vascular procedures. Verdye’s entry into Singapore enhances access to a globally established product with a strong track record across international markets.
This latest milestone builds on UltraGreen.ai’s recent IPO and regulatory approval of Verdye in the Philippines, underscoring strong execution and the company’s long-term commitment to advancing precision surgery through high-quality pharmaceutical, imaging, and data-driven solutions. Verdye is now approved in 41 countries globally, with the IC-Flow™ imaging system cleared in 45 markets.
